Akebia Therapeutics Inc. (NASDAQ:AKBA) was up $1.87 (14%) to $14.77 in after-hours trading after it said it granted Vifor Pharma Group (SIX:VIFN) exclusive U.S. distribution rights to vadadustat (formerly AKB-6548)
Read the full 309 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury